Related Experiment Video
Updated: May 12, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton
Expert Review of Hematology
|April 4, 2013
Summary
Professor John Gribben
Area of Science:
- Medical Oncology
- Hematology
- Cancer Research
Background:
- Professor John Gribben's extensive career in medical oncology and cancer research.
- His leadership roles include Chair of the International Workshop on non-Hodgkin Lymphoma.
- Affiliated with St. Bartholomew's Hospital, Bart's Cancer Institute, and Cancer Research UK.
Discussion:
- Gribben's research interests encompass the immunotherapy of cancer, including stem cell transplantation.
- He is dedicated to identifying B-cell-tumor antigens for targeted therapies.
- His work also focuses on the detection and treatment of minimal residual disease in leukemia and lymphoma.
Key Insights:
- Gribben's expertise lies in advancing cancer treatment through immunotherapy and understanding B-cell malignancies.
- His contributions are vital for developing novel strategies against leukemia and lymphoma.
Outlook:
- Continued research into immunotherapy and minimal residual disease holds promise for improved patient outcomes.
- Further identification of B-cell-tumor antigens could lead to more effective and personalized cancer therapies.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...